Drug intelligence / Profile preview

Fh15

Development stage: Preclinical
Lead developer: University of Puerto Rico
Modality: Recombinant Proteins and Enzymes
Administration: Intraperitoneal

Overview

Fh15 is a recombinant fatty acid-binding protein (FABP) derived from the helminth parasite *Fasciola hepatica*. It acts as a Toll-like receptor 4 (TLR4) antagonist, possessing potent anti-inflammatory properties. Developed by researchers at the University of Puerto Rico, Fh15 has been shown to suppress the pathological presentations of ulcerative colitis in murine models by reducing disease activity, histopathological scores, and inflammatory markers such as myeloperoxidase (MPO), CHI3L1, and S100. Additionally, Fh15 has demonstrated efficacy in murine and non-human primate models of sepsis, suggesting its potential as a therapeutic for various TLR4-mediated inflammatory conditions.

Other names: Fasciola hepatica fatty acid binding proteinFhFABP

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on Fh15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fh15.

Explore the full profile